Positron Emission Tomography News and Research

RSS

Spectrum announces various clinical studies on ZEVALIN at ICML 2011

Spectrum Pharmaceuticals, a biotechnology company with fully integrated commercial and drug development operations with a primary focus in oncology, today announced that various studies on ZEVALIN for Injection were presented at the 11th International Conference on Malignant Lymphoma (ICML), held June 15-18, 2011, in Lugano, Switzerland.

20 Jun 2011

European scientists develop efficient methods for early diagnosis of Alzheimer's

PredictAD is an EU-funded research project that develops objective and efficient methods for enabling earlier diagnosis of Alzheimer's disease. Diagnosis requires a holistic view of the patient combining information from several sources, such as, clinical tests, imaging and blood samples.

16 Jun 2011

Dual Body scan machine gets FDA nod

According to the U.S. Food and Drug Administration last Friday, Siemens AG's device that simultaneously performs two common diagnostic tests received clearance from them. The German engineering company's U.S.-based Siemens Medical Solutions, which is based in Pennsylvania, manufactures the device.

From Siemens Healthineers 13 Jun 2011

Siemens receives FDA clearance for Biograph mMR system to perform simultaneous PET/MRI scan

The U.S. Food and Drug Administration today cleared the Siemens Biograph mMR system, the first device to simultaneously perform a positron emission tomography scan, commonly known as PET scan, and a magnetic resonance imaging (MRI) scan.

From Siemens Healthineers 13 Jun 2011

Synta presents ganetespib Phase 1, 2 trial results against solid tumors at ASCO 2011

Synta Pharmaceuticals Corp. today presented results at the Annual Meeting of the American Society for Clinical Oncology (ASCO) from a Phase 2 single agent clinical trial of ganetespib in gastrointestinal stromal tumors (GIST) and a Phase 1 trial of ganetespib in solid tumors evaluating a twice-weekly administration schedule.

7 Jun 2011

ImaginAb, Oxford BioMedicaplc enter research deal to develop in vivo diagnostic imaging agent

Oxford BioMedicaplc, a leading gene therapy company, today announces that it has signed a research collaboration agreement with ImaginAb, Inc., a biotechnology company specialising in the development of engineered antibody fragments for diagnostic imaging and novel therapeutic applications, to engineer an in vivo diagnostic imaging agent using an antibody targeting the Company's proprietary 5T4 tumour antigen.

7 Jun 2011

New UH Seidman Cancer Center center to offer latest treatments and technology

University Hospitals (UH) Seidman Cancer Center, Northeast Ohio's first and only freestanding cancer hospital, opens to patients on June 6. The ten-story, 150-bed cancer hospital will house the latest cancer-fighting treatments and technology – all in a patient-centered, healing-focused environment.

6 Jun 2011

ImaginAb, GE Healthcare sign master research deal to develop new PET diagnostic imaging agents

GE Healthcare Ltd. and ImaginAb, Inc. have executed a master research agreement around the development of new PET (Positron Emission Tomography) diagnostic imaging agents based on ImaginAb's antibody fragment technology. The agreement is launched with an initial exclusive collaboration around a novel cardiovascular target.

6 Jun 2011

Ipilimumab and bevacizumab drugs effective in treating metatastic melanoma

A duo of drugs, each targeting a prime survival strategy of tumors, can be safely administered and are potentially more effective than either drug alone for advanced, inoperable melanomas, according to a phase 1 clinical trial led by Dana-Farber Cancer Institute investigators.

4 Jun 2011

PCF funds 14 new Creativity Awards for advanced prostate cancer research

The Prostate Cancer Foundation today announced that it has funded 14 new Creativity Awards for advanced prostate cancer research. These two-year awards are designed to support innovative research ideas that have the potential to achieve breakthroughs for improved prostate cancer diagnosis and treatment.

2 Jun 2011

PET scans can help determine patients' response to treatment for HIV-MDR tuberculosis

With the deficiencies in knowledge of tuberculosis-as well as in the practices, programs and strategies used to combat the disease and co-infection with human immunodeficiency virus-the spread of multidrug-resistant tuberculosis poses a major problem for the health care community.

25 May 2011

Study shows why individuals with anorexia nervosa have paradoxical response to food

Perhaps the most puzzling symptom of anorexia nervosa - a disorder that tends to occur in young women - is the refusal to eat, resulting in extreme weight loss. While most people have a great deal of difficulty in dieting and losing weight, particularly if a diet extends over many months or years, individuals with anorexia nervosa can literally diet themselves to death. In fact, this disorder has a very high death rate from starvation.

21 May 2011

Clinical PET system for early stage breast cancer diagnosis

European researchers have developed a clinical PET system with the highest resolution and sensitivity in the market, specifically dedicated to breast cancer detection in early stages.

18 May 2011

Phase 2 trial data of PET myocardial perfusion imaging with flurpiridaz F 18 presented at ICNC10

Lantheus Medical Imaging, Inc., a worldwide leader in diagnostic imaging, today announced data from a Phase 2 clinical trial that demonstrated Positron Emission Tomography myocardial perfusion imaging with flurpiridaz F 18 provided superior image quality, diagnostic certainty and diagnostic performance for detecting coronary artery disease (CAD) compared to single photon emission computed tomography myocardial perfusion imaging, the current standard for the non-invasive detection of CAD.

17 May 2011

'Mu opioid' receptors in the brain linked to smoking relapse

Nearly everyone who has tried to quit smoking says it's incredibly difficult, and the struggle is due in part to genetic factors. Now, a new study from the Raymond and Ruth Perelman School of Medicine at the University of Pennsylvania sheds light on how one specific genetic risk for smoking relapse may work: Some of the difficulties may be due to how many receptors, called "mu opioid" receptors, a smoker has in his or her brain.

17 May 2011

Study shows how secondhand smoke may increase vulnerability to nicotine addiction

Exposure to secondhand smoke, such as a person can get by riding in an enclosed car while someone else smokes, has a direct, measurable impact on the brain-and the effect is similar to what happens in the brain of the person doing the smoking.

3 May 2011

No proven advantages of PET for diagnostic accuracy of head and neck tumours: Research

The benefit and harm of positron emission tomography in patients with head and neck tumours, applied alone or in combination with computed tomography, cannot currently be reliably assessed.

30 Apr 2011

Combining CT with FDG-PET improves treatment options for head, neck cancer patients

Combining computerized tomography with fluorodeoxyglucose positron emission tomography images results in significantly more defined tumor outlines and potentially different treatment options in head and neck cancer patients compared to using CT alone, according to research presented today, at the Cancer Imaging and Radiation Therapy Symposium in Atlanta.

30 Apr 2011

Brain function variations may increase person's risk of drug abuse

One can look at drug addiction as a moral issue, a social ill, or a criminal problem. But Lynn Oswald's experience studying the neuroscience of addiction tells her that it is something else entirely: a disease of the brain.

30 Apr 2011

New PET imaging clinical trial to improve early esophageal, lung cancer detection

Can a simple imaging test help predict the success of cancer treatment, even before the treatment is complete? To begin to answer this question, a new National Cancer Institute-funded clinical trial is using a novel PET imaging technique that could improve the early detection of tumor growth during treatment for esophageal and lung cancer.

29 Apr 2011

Positron Emission Tomography News and Research

Spectrum announces various clinical studies on ZEVALIN at ICML 2011

European scientists develop efficient methods for early diagnosis of Alzheimer's

Dual Body scan machine gets FDA nod

Siemens receives FDA clearance for Biograph mMR system to perform simultaneous PET/MRI scan

Synta presents ganetespib Phase 1, 2 trial results against solid tumors at ASCO 2011

ImaginAb, Oxford BioMedicaplc enter research deal to develop in vivo diagnostic imaging agent

New UH Seidman Cancer Center center to offer latest treatments and technology

ImaginAb, GE Healthcare sign master research deal to develop new PET diagnostic imaging agents

Ipilimumab and bevacizumab drugs effective in treating metatastic melanoma

PCF funds 14 new Creativity Awards for advanced prostate cancer research

PET scans can help determine patients' response to treatment for HIV-MDR tuberculosis

Study shows why individuals with anorexia nervosa have paradoxical response to food

Clinical PET system for early stage breast cancer diagnosis

Phase 2 trial data of PET myocardial perfusion imaging with flurpiridaz F 18 presented at ICNC10

'Mu opioid' receptors in the brain linked to smoking relapse

Study shows how secondhand smoke may increase vulnerability to nicotine addiction

No proven advantages of PET for diagnostic accuracy of head and neck tumours: Research

Combining CT with FDG-PET improves treatment options for head, neck cancer patients

Brain function variations may increase person's risk of drug abuse

New PET imaging clinical trial to improve early esophageal, lung cancer detection

Industry Focus eBook - Analytical Chemistry (2nd Edition) eBook

Improving healthcare sustainability through carbon data

Managing vibration in IVF laboratories

A New Approach to Preventing Bladder Cancer Recurrence

Latest News